Table 2.
HIV data Results (N=385)
| Characteristic1 | |
|---|---|
| Log10 viral load (copies/mL): | |
| Mean (SD) | 3.1 (1.3) |
| Median | 2.6 |
| Viral load: n (%) | |
| Undetectable (<400 copies/mL) | 130 (34.2) |
| Detectable (≥ 400 copies/mL) | 250 (65.8) |
| Missing | 5 |
| CD4 count percent: n (%) | |
| <15% | 19 (5.0) |
| 15 to 25% | 89 (23.4) |
| >25% | 272 (71.6) |
| Missing | 5 |
| CD4 count (cells/mm3): n (%) | |
| <200 | 5 (1.3) |
| 200–499 | 40 (10.4) |
| ≥500 | 340 (88.3) |
| CDC Classification: n (%) | |
| N | 28 (7.3) |
| A | 105 (27.3) |
| B | 116 (30.2) |
| C | 135 (35.2) |
| Missing | 1 |
| WHO immunological staging: n (%) | |
| None or not significant | 233 (61.3) |
| Mild | 43 (11.3) |
| Advanced | 33 (8.7) |
| Severe | 71 (18.7) |
| Missing | 5 |
| Any ART prior to eligibility: n (%) | |
| Yes | 344 (89.4) |
| No | 41 (10.6) |
| Duration of exposure to ART prior to eligibility (years): | |
| Mean (SD) | 4.6 (2.8) |
| Median | 4.5 |
| Current ART regimen type: n (%) | |
| No ART | 68 (17.7) |
| PI-containing regimen | 214 (55.6) |
| Non-PI-containing regimen | 103 (26.8) |
| Self-reported ART adherence among those receiving ART2
: n (%) |
|
| 100% adherence | 279 (89.4) |
| <100% adherence | 33 (10.6) |
| Missing | 73 |
1
Where not available at time of eligibility, the most recent result prior to eligibility was selected. Missing data were not included in percentage calculations.
2
Percent adherence was determined in terms of numbers of ART doses missed relative to doses expected to be taken during the 3 day period prior to the study visit.